225 related articles for article (PubMed ID: 16509866)
1. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
[TBL] [Abstract][Full Text] [Related]
2. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.
Hassanein T; Cooksley G; Sulkowski M; Smith C; Marinos G; Lai MY; Pastore G; Trejo-Estrada R; Horta E Vale A; Wintfeld N; Green J
J Hepatol; 2004 Apr; 40(4):675-81. PubMed ID: 15030985
[TBL] [Abstract][Full Text] [Related]
3. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
Bini EJ; Mehandru S
Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
[TBL] [Abstract][Full Text] [Related]
4. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
Hornberger J; Farci P; Prati D; Zeuzem S; Green J; Patel KK
J Viral Hepat; 2006 Jun; 13(6):377-86. PubMed ID: 16842440
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.
Keating GM; Plosker GL
Drugs; 2005; 65(4):521-36. PubMed ID: 15733013
[TBL] [Abstract][Full Text] [Related]
7. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
Dusheiko G; Danta M
Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
[No Abstract] [Full Text] [Related]
8. Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.
Al-Ali J; Siddique I; Varghese R; Hasan F
Ann Hepatol; 2012; 11(2):186-93. PubMed ID: 22345335
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
10. Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment.
Nakamura M; Kanda T; Miyamura T; Wu S; Nakamoto S; Yokosuka O
Int J Med Sci; 2013; 10(8):1015-21. PubMed ID: 23801888
[TBL] [Abstract][Full Text] [Related]
11. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Snoeck E; Hadziyannis SJ; Puoti C; Swain MG; Berg T; Marcellin P; Zarski JP; Jorga K; Zeuzem S
Liver Int; 2008 Jan; 28(1):61-71. PubMed ID: 17971091
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
Keam SJ; Cvetković RS
BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
[TBL] [Abstract][Full Text] [Related]
13. Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
Puoti C; Barbarini G; Picardi A; Romano M; Pellicelli A; Barlattani A; Mecenate F; Guarisco R; Costanza OM; Spilabotti L; Bellis L; Bonaventura ME; Dell' Unto O; Elmo MG; Nicolini AM; Nosotti L; Soccorsi F;
J Viral Hepat; 2011 Jun; 18(6):393-9. PubMed ID: 20546499
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
Zeuzem S; Diago M; Gane E; Reddy KR; Pockros P; Prati D; Shiffman M; Farci P; Gitlin N; O'Brien CB; Lamour F; Lardelli P;
Gastroenterology; 2004 Dec; 127(6):1724-32. PubMed ID: 15578510
[TBL] [Abstract][Full Text] [Related]
15. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
Berg C; Goncales FL; Bernstein DE; Sette H; Rasenack J; Diago M; Jensen DM; Graham P; Cooksley G
J Viral Hepat; 2006 Jul; 13(7):435-40. PubMed ID: 16792536
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon α-2a and rivabirin in the treatment of chronic hepatitis C.
Rahman MZ; Perveen S; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Huda MN; Ahmed DS; Raihan MA
Mymensingh Med J; 2014 Apr; 23(2):335-40. PubMed ID: 24858163
[TBL] [Abstract][Full Text] [Related]
18. A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Gerkens S; Nechelput M; Annemans L; Peraux B; Beguin C; Horsmans Y
Acta Gastroenterol Belg; 2007; 70(2):177-87. PubMed ID: 17715631
[TBL] [Abstract][Full Text] [Related]
19. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
[TBL] [Abstract][Full Text] [Related]
20. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
Deuffic-Burban S; Babany G; Lonjon-Domanec I; Deltenre P; Canva-Delcambre V; Dharancy S; Louvet A; Roudot-Thoraval F; Mathurin P
Hepatology; 2009 Nov; 50(5):1351-9. PubMed ID: 19676130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
